Comparison of the abbott realtime high-risk human papillomavirus (HPV), roche cobas HPV, and hybrid capture 2 assays to direct sequencing and genotyping of HPV DNA

Journal of Clinical Microbiology

Volumn 50, Issue 7, 2012, Pages 2359-2365

  Park, Yongjung ^a   Lee, Eunhee ^b   Choi, Jonghyeon ^a   Jeong, Seri ^a   Kim, Hyon Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Green Cross Reference Laboratory   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABBOTT REALTIME HIGH RISK HUMAN PAPILLOMAVIRUS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CRITERION VARIABLE; CYTOLOGY; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; HYBRID CAPTURE 2 ASSAY; MOLECULAR TYPING; PAPILLOMA VIRUS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ROCHE COBAS HUMAN PAPILLOMAVIRUS; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION;

CERVIX UTERI; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; VIROLOGY;

EID: 84862742577     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00337-12     Document Type: Article

References (36)

1. Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. 2000. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J. Natl. Cancer Inst. 92:397-402.
2. Bosch FX, et al. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26(Suppl 10):K1-K16.
3. Bouvard V, et al. 2009. A review of human carcinogens - part B: biological agents. Lancet Oncol. 10:321-322.
4. Carozzi FM, et al. 2011. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of Hybrid Capture 2 assay in a screening setting. J. Clin. Microbiol. 49:1446-1451.
5. Castle PE, et al. 2009. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J. Clin. Microbiol. 47:3344-3347.
6. Clifford GM, et al. 2005. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol. Biomarkers Prev. 14:1157-1164.
7. Cuzick J, et al. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:1095-1101.
8. Eom JH, Park SB, Zhang BT. 2004. Genetic mining of DNA sequence structures for effective classification of the risk types of human papillomavirus (HPV), p 1334-1343. In Proceedings of the International Conference on Neural Information Processing. Springer, Berlin, Germany.
9. Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler CM. 2009. EUROGIN 2008 roadmap on cervical cancer prevention. Int. J. Cancer 125:2246-2255.
10. Gage JC, et al. 2012. Comparison of the cobas human papillomavirus (HPV) test with the Hybrid Capture 2 and Linear Array HPV DNA tests. J. Clin. Microbiol. 50:61-65.
11. Ginocchio CC, Barth D, Zhang F. 2008. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the Digene HPV Hybrid Capture 2 assay for detection of high-risk HPV DNA. J. Clin. Microbiol. 46:1641-1646.
12. Gustafsson L, Ponten J, Bergstrom R, Adami HO. 1997. International incidence rates of invasive cervical cancer before cytological screening. Int. J. Cancer 71:159-165.
13. Gustafsson L, Ponten J, Zack M, Adami HO. 1997. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 8:755-763.
14. Halfon P, et al. 2010. Stepwise algorithm combining HPV high-risk DNA-based assays and RNA-based assay for high grade CIN in women with abnormal smears referred to colposcopy. Cancer Biomark. 7:133-139.
15. Huang S, et al. 2009. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J. Clin. Virol. 45(Suppl 1):S19-S23.
16. Kaliterna V, Lepej SZ, Vince A. 2009. Comparison between the Abbott RealTime High Risk HPV assay and the Hybrid Capture 2 assay for detecting high-risk human papillomavirus DNA in cervical specimens. J. Med. Microbiol. 58:1662-1663.
17. Kovacic MB, et al. 2006. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 66:10112-10119.
18. Lapierre SG, et al. 2012. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J. Clin. Microbiol. 50:1240-1244.
19. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. 2011. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer 128:927-935.
20. Lindemann ML, et al. 2012. Analytical comparison of the cobas HPV test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J. Mol. Diagn. 14:65-70.
21. Mo LZ, et al. 2008. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA genotyping assay to screen the discordant results. J. Clin. Virol. 41:104-110.
22. Nayar R, Solomon D. 2004. Second edition of 'The Bethesda System for reporting cervical cytology' - Atlas, website, and Bethesda interobserver reproducibility project. Cytojournal 1:4.
23. Poljak M, Brencic A, Seme K, Vince A, Marin IJ. 1999. Comparative evaluation of first- and second-generation Digene Hybrid Capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. J. Clin. Microbiol. 37:796-797.
24. Poljak M, et al. 2011. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of Hybrid Capture 2 in population-based cervical cancer screening. J. Clin. Microbiol. 49:1721-1729.
25. Ratnam S, et al. 2011. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 assay but more specific at detecting cervical precancer and cancer. J. Clin. Microbiol. 49:557-564.
26. Ratnam S, et al. 2010. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J. Clin. Microbiol. 48:2779-2785.
27. Sandri MT, et al. 2006. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol. 44:2141-2146.
28. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. 2007. Human papillomavirus and cervical cancer. Lancet 370:890-907.
29. Schiffman M, et al. 2011. Human papillomavirus testing in the prevention of cervical cancer. J. Natl. Cancer Inst. 103:368-383.
30. Schiffman M, Wheeler CM, Castle PE. 2002. Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormalities. J. Infect. Dis. 186:1169-1172.
31. Smith JS, et al. 2007. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121:621-632.
32. Stevens MP, et al. 2007. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J. Clin. Microbiol. 45:2130-2137.
33. Venturoli S, et al. 2012. Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting. J. Clin. Virol. 53:121-124.
34. Wong AA, Fuller J, Pabbaraju K, Wong S, Zahariadis G. 2012. Comparison of the Hybrid Capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium. J. Clin. Microbiol. 50:25-29.
35. World Health Organization. 2010. Strengthening cervical cancer prevention and control: report of the GAVI-UNFPA-WHO meeting. December 2009. WHO/RHR/10.13. World Health Organization, Geneva, Switzerland.
36. World Health Organization and Department of Reproductive Health and Research. 2008. Cervical cancer, human papillomavirus (HPV), and HPV vaccines: Key points for policy-makers and health professionals. WHO/RHR/08.14. World Health Organization, Geneva, Switzerland.